Allogene Therapeutics announced Monday that its off-the-shelf CAR-T therapy cema-cel met the interim goal of a Phase 3 clinical trial, achieving minimal residual disease negativity in 58% of B-cell lymphoma patients compared to 16% in the observation group. The allogeneic treatment eliminated residual cancer cells three times better than standard care and could become the first cell therapy designed to delay or prevent cancer recurrence in high-risk lymphoma patients completing first-line treatment. Unlike traditional CAR-T therapies requiring personalized manufacturing, cema-cel is designed as an easily administered off-the-shelf product that could offer faster access to treatment for patients at high risk of relapse.
Phase 3 Trial Results for Cema-cel CAR-T Therapy
- ▪Cema-cel is an off-the-shelf CAR-T treatment developed by Allogene Therapeutics
- ▪In the interim analysis of the Phase 3 trial, 58% of patients treated with cema-cel achieved minimal residual disease negativity
- ▪Cema-cel eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care
- ▪Allogene Therapeutics announced on Monday that cema-cel achieved the interim goal of an ongoing Phase 3 clinical trial
Potential Clinical Impact on B-Cell Lymphoma Treatment
- ▪Cema-cel could delay or prevent the recurrence of cancer in patients with a high risk of lymphoma relapse at the end of first-line treatment
- ▪Cema-cel is designed to be an easily administered cell therapy for B-cell lymphoma patients
Perspective of Allogene Therapeutics
- ▪The off-the-shelf nature of cema-cel addresses manufacturing and timing challenges associated with traditional autologous CAR-T therapies
- ▪Cema-cel represents a potential paradigm shift in making CAR-T therapy more accessible to patients with B-cell lymphoma
Perspective of B-cell lymphoma patients with high relapse risk
- ▪High-risk B-cell lymphoma patients currently lack approved cell therapy options specifically designed to prevent cancer recurrence after first-line treatment
- ▪Cema-cel offers B-cell lymphoma patients in remission a potential option to prevent relapse without waiting for personalized cell therapy manufacturing
Story comments
Loading comments…